The enzymatic conversion of progesterone and testosterone by the enzyme 5alpha-reductase exerts a crucial role in the control of nervous function. The effects of finasteride in the brain, an inhibitor of this enzyme used for the treatment of human benign prostatic hyperplasia and androgenic alope- cia, have been poorly explored. Therefore, the effects of a subchronic treatment with finasteride at low doses (3 mg/ kg/day) and the consequences of its withdrawal on neuroac- tive steroid levels in plasma, cerebrospinal fluid and some brain regions as well as on the expression of classical and non-classical steroid receptors have been evaluated in male rats. After subchronic treatment (i.e., for 20 days) the follow- ing effects were detected: (i) depending on the compart- ment considered, alteration in the levels of neuroactive ste- roids, not only in 5alpha-reduced metabolites but also in its precursors and in neuroactive steroids from other steroido- genic pathways and (ii) an upregulation of the androgen receptor in the cerebral cortex and beta3 subunit of the GABA-A receptor in the cerebellum. One month after the last treatment (i.e., withdrawal period), some of these effects persisted (i.e., the upregulation of the androgen receptor in the cerebral cortex, an increase of dihydroprogesterone in the cerebellum, a decrease of dihydrotestosterone in plas- ma). Moreover, other changes in neuroactive steroid levels, steroid receptors (i.e., an upregulation of the estrogen recep- tor alpha and a downregulation of the estrogen receptor beta in the cerebral cortex) and GABA-A receptor subunits (i.e., a decrease of alpha 4 and beta 3 mRNA levels in the ce- rebral cortex) were detected. These findings suggest that fi- nasteride treatment may have broad consequences for brain function.

Effects of Subchronic Finasteride Treatment and Withdrawal on Neuroactive Steroid Levels and their Receptors in the Male Rat Brain

FOGLIO, BENEDETTA;PANZICA, Giancarlo;
2016

Abstract

The enzymatic conversion of progesterone and testosterone by the enzyme 5alpha-reductase exerts a crucial role in the control of nervous function. The effects of finasteride in the brain, an inhibitor of this enzyme used for the treatment of human benign prostatic hyperplasia and androgenic alope- cia, have been poorly explored. Therefore, the effects of a subchronic treatment with finasteride at low doses (3 mg/ kg/day) and the consequences of its withdrawal on neuroac- tive steroid levels in plasma, cerebrospinal fluid and some brain regions as well as on the expression of classical and non-classical steroid receptors have been evaluated in male rats. After subchronic treatment (i.e., for 20 days) the follow- ing effects were detected: (i) depending on the compart- ment considered, alteration in the levels of neuroactive ste- roids, not only in 5alpha-reduced metabolites but also in its precursors and in neuroactive steroids from other steroido- genic pathways and (ii) an upregulation of the androgen receptor in the cerebral cortex and beta3 subunit of the GABA-A receptor in the cerebellum. One month after the last treatment (i.e., withdrawal period), some of these effects persisted (i.e., the upregulation of the androgen receptor in the cerebral cortex, an increase of dihydroprogesterone in the cerebellum, a decrease of dihydrotestosterone in plas- ma). Moreover, other changes in neuroactive steroid levels, steroid receptors (i.e., an upregulation of the estrogen recep- tor alpha and a downregulation of the estrogen receptor beta in the cerebral cortex) and GABA-A receptor subunits (i.e., a decrease of alpha 4 and beta 3 mRNA levels in the ce- rebral cortex) were detected. These findings suggest that fi- nasteride treatment may have broad consequences for brain function.
103
746
757
www.karger.com/journals/nen/nen_jh.htm
Endocrinology; Endocrinology, Diabetes and Metabolism; Endocrine and Autonomic Systems; Cellular and Molecular Neuroscience
Giatti, Silvia; Foglio, Benedetta; Romano, Simone; Pesaresi, Marzia; Panzica, Giancarlo; Garcia-Segura, Luis Miguel; Caruso, Donatella; Melcangi, Roberto C.
File in questo prodotto:
File Dimensione Formato  
2016GiattiNeuroEndo.pdf

Accesso riservato

Descrizione: 2016GiattiNEndo
Tipo di file: PDF EDITORIALE
Dimensione 242.09 kB
Formato Adobe PDF
242.09 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
2016GiattiNeuroEndo-4aperto.pdf

Accesso aperto con embargo fino al 01/09/2017

Descrizione: 2016GiattiNEndo-aperto
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 864.29 kB
Formato Adobe PDF
864.29 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1616906
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 26
social impact